Background: Patients with established primary parvovirus infection are at risk of adverse pregnancy outcomes. In addition to the normal checkup for fetal hydrops or intrauterine mortalities, investigation of parvovirus B19 infection was advised. Aim and objectives: The aim of the study is to assess the frequency of parvovirus B19 infection in cases of unexplained intrauterine fetal death, non-immune hydrops, and abortion. Subjects and methods: This study was a cross-sectional study that included 60 female patients who suffered from unexplained intra-uterine fetal death, abortion or, non-immune hydrops during six months. All patients fulfilling the inclusion criteria were recruited from Obstetrics and Gynaecology Department of Zagazig University hospitals and Suez Health Insurance Hospital. All participants were subjected to complete history taking with special emphasis on obstetric and prenatal history. Ultrasound examination was performed for all participants to confirm IUFD, abortion or hydrops and to exclude other fetal anomalies not included in our study. We did other investigations including routine laboratory investigations in addition venous blood sampling for detection of human parvovirus B19 antibody IgM and IgG in these samples. Results: The presence of seropositive parvovirus B19 IgG was 43.3% and the presence of parvovirus B19 IgM was 5%. Regarding the seropositivity for parvovirus B19 in the studied cases, there was no statistically significant difference between negative and positive groups. Conclusion: The study showed that 48.3% of the women with unexplained intrauterine fetal death, abortion, or non-immune hydrops were seropositive for HPV B19.